Literature DB >> 36267894

It is time to end our love affair with short-acting β2-agonists in asthma.

Michael G Crooks1,2, Shoaib Faruqi2.   

Abstract

In this issue of ERJOR, Noorduynet al. add data to the growing literature showing that SABA overuse in asthma is both common and associated with severe exacerbations. It is time to take note and act to tackle this global issue. https://bit.ly/3BfwhfS.
Copyright ©The authors 2022.

Entities:  

Year:  2022        PMID： 36267894      PMCID： PMC9574554          DOI： 10.1183/23120541.00353-2022

Source DB:  PubMed          Journal:  ERJ Open Res        ISSN： 2312-0541


  27 in total

1.  Sir David Jack: an extraordinary drug discoverer and developer.

Authors:  Clive Page; Patrick Humphrey
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

2.  The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma.

Authors:  T Haahtela; K Alanko; A Muittari; A Lahdensuo; K Sahlström; V Vilkka
Journal:  Ann Allergy       Date:  1989-01

3.  Identifying the drivers of patients' reliance on short-acting β2-agonists in asthma.

Authors:  Sarah Blakeston; Gavin Harper; Julen Zabala Mancebo
Journal:  J Asthma       Date:  2020-05-29       Impact factor: 2.515

4.  Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.

Authors:  Eric D Bateman; David B Price; Hao-Chien Wang; Adel Khattab; Patricia Schonffeldt; Angelina Catanzariti; Ralf J P van der Valk; Maarten J H I Beekman
Journal:  Eur Respir J       Date:  2022-05-05       Impact factor: 33.795

5.  Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.

Authors:  Alberto Papi; Massimo Corradi; Catherine Pigeon-Francisco; Roberta Baronio; Zenon Siergiejko; Stefano Petruzzelli; Leonardo M Fabbri; Klaus F Rabe
Journal:  Lancet Respir Med       Date:  2013-03-04       Impact factor: 30.700

6.  Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.

Authors:  Iain Crossingham; Sally Turner; Sanjay Ramakrishnan; Anastasia Fries; Matthew Gowell; Farhat Yasmin; Rebekah Richardson; Philip Webb; Emily O'Boyle; Timothy Sc Hinks
Journal:  Cochrane Database Syst Rev       Date:  2021-05-04

7.  SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries.

Authors:  Christer Janson; Andrew Menzies-Gow; Cassandra Nan; Javier Nuevo; Alberto Papi; Jennifer K Quint; Santiago Quirce; Claus F Vogelmeier
Journal:  Adv Ther       Date:  2020-01-24       Impact factor: 3.845

8.  Carbon footprint impact of the choice of inhalers for asthma and COPD.

Authors:  Christer Janson; Richard Henderson; Magnus Löfdahl; Martin Hedberg; Raj Sharma; Alexander J K Wilkinson
Journal:  Thorax       Date:  2019-11-07       Impact factor: 9.139

9.  Towards codesign in respiratory care: development of an implementation-ready intervention to improve guideline-adherent adult asthma care across primary and secondary care settings (The SENTINEL Project).

Authors:  Lucia Crowther; Mark Pearson; Helena Cummings; Michael George Crooks
Journal:  BMJ Open Respir Res       Date:  2022-02

10.  The Burden of Short-Acting β2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.

Authors:  Fabiano Di Marco; Mariella D'Amato; Francesco P Lombardo; Claudio Micheletto; Franca Heiman; Valeria Pegoraro; Silvia Boarino; Giandomenico Manna; Francesca Mastromauro; Simona Spennato; Alberto Papi
Journal:  Adv Ther       Date:  2021-05-27       Impact factor: 3.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.